SST and Hypoglycemia: Compared to β-cell factors, a conceptual advantage of somatostatin-mediated glucose inhibition of glucagon release is that it may operate also in hypoglycaemia, since glucose stimulates somatostatin release from mouse and human islets at similar concentrations that inhibit glucagon secretion (Figure 1) (39–41).